Overall survival according to cytology (blastoid variant vs classical MCL). (A) MCL younger: younger patients (n = 325) received R-CHOP with or without R-DHAP (rituximab, dexamethasone, high dose cytarabine, cisplatinum), followed by autologous stem cell transplantation. (B) MCL elderly: older patients (n = 295) were treated with R-CHOP vs R-FC (rituximab, fludarabine, cyclophosphamide), followed by interferon/rituximab maintenance.